NEW YORK — SEngine Precision Medicine and Atomwise announced today that they have partnered to develop new personalized treatments for cancer.
Under the alliance, San Francisco-based Atomwise will use its artificial intelligence technology to discover and develop small molecule inhibitors against gene targets, provided by SEngine, essential for cancer cell growth.